Provided by Tiger Trade Technology Pte. Ltd.

Personalis

7.78
+0.17002.23%
Volume:849.91K
Turnover:6.56M
Market Cap:814.04M
PE:-8.54
High:7.91
Open:7.49
Low:7.40
Close:7.61
52wk High:11.50
52wk Low:2.83
Shares:104.63M
Float Shares:68.12M
Volume Ratio:0.63
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9107
EPS(LYR):-0.9107
ROE:-35.02%
ROA:-18.21%
PB:3.12
PE(LYR):-8.54

Loading ...

Personalis Stock Falls on Preliminary 4Q Results

Dow Jones
·
Jan 09

Personalis Preliminary Q4 Revenue Within Analyst Range

MT Newswires Live
·
Jan 08

BRIEF-Personalis Reports Select Preliminary Fourth Quarter And Full Year 2025 Results

Reuters
·
Jan 08

GUIDANCE: (PSNL) Personalis Expects Fiscal Q4 Revenue Range $17M to $18M, vs. FactSet Est of $17.6M

MT Newswires Live
·
Jan 08

Personalis Inc - Preliminary Q4 Revenue of $17-$18 Mln

THOMSON REUTERS
·
Jan 08

Press Release: Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Dow Jones
·
Jan 08

BRIEF-Personalis Announces New Publication Applying Ultrasensitive CtDNA Testing

Reuters
·
Dec 17, 2025

Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors

Reuters
·
Dec 17, 2025

Personalis Announces New Publication Applying Ultrasensitive Ctdna Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

THOMSON REUTERS
·
Dec 17, 2025

Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study

Reuters
·
Dec 11, 2025

Personalis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Dec 03, 2025

Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating

MT Newswires Live
·
Dec 02, 2025

Personalis Announces $100M Stock Offering Amendment

TIPRANKS
·
Nov 29, 2025

Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares

Reuters
·
Nov 29, 2025

Personalis (PSNL) Gets a Buy from Lake Street

TIPRANKS
·
Nov 25, 2025

BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers

Reuters
·
Nov 25, 2025

Personalis Inc - Effective December 1, Reimbursement Rate for Next Personal Dx Breast Mrd Test Set at $4,266 - SEC Filing

THOMSON REUTERS
·
Nov 25, 2025

Personalis Inc - CMS Revises Reimbursement Rate for Next Personal Test for Post-Treatment Surveillance of Cancer - SEC Filing

THOMSON REUTERS
·
Nov 25, 2025

Stock Track | Personalis Soars 5.24% After-Hours on Bullish Analyst Ratings and Price Target Hike

Stock Track
·
Nov 12, 2025

Stock Track | Personalis Soars 5.24% After-Hours on Positive Analyst Ratings and Price Target Boost

Stock Track
·
Nov 12, 2025